Submit your paper
Search
Menu
Home All issues Volume 24 / No 4 (December 2018) J Oral Med Oral Surg, 24 4 (2018) 187-191 References
Open Access
Issue
J Oral Med Oral Surg
Volume 24, Number 4, December 2018
Page(s) 187 - 191
Section Cas clinique et revue de la littérature / Up-to date review and case report
DOI https://doi.org/10.1051/mbcb/2018021
Published online 17 December 2018
  1. Barthélémy I, Mondie JM. Tumeurs et pseudotumeurs des maxillaires riches en cellules géantes. Rev Stomat chir maxilfac 2009;110:209–213. [CrossRef] [PubMed] [Google Scholar]
  2. Baumhoer D. Bone-related lesions of the jaws. Surg Pathol Clin 2017;10:693–704. [CrossRef] [PubMed] [Google Scholar]
  3. Victorin A, Vincent S, Duvillard C, Larras P, Petrella T, Perrin D. Granulome réparateur à cellules géantes du maxillaire: à propos d'un cas. Rev Odont Stomat 2010;39:135–144. [Google Scholar]
  4. Stravopoulos F, Katz J. Central giant granulomas: a systematic review of the radiographic characteristics with the addition of 20 new cases. Dentmaxilfac Rad 2003;31: 213–217. [CrossRef] [Google Scholar]
  5. Chuong R, Kaban LB, Kozakewich H, Perez-Atayde A. Central giant cell lesions of the jaws: a clinicopathologic study. J Oral Maxillofac Surg 1986;44:708–13. [CrossRef] [PubMed] [Google Scholar]
  6. Dewsnup NC, Susarla SM, Abulikemu M, Faquin WC, Kaban LB, August M. Immunohistochemical evaluation of giant cell tumors of the jaws using CD34 density analysis. J Oral Maxillofac Surg. 2008;66:928–933. [CrossRef] [PubMed] [Google Scholar]
  7. Ficarra G, Kaban LB, Harsen LS. Central Giant cell lesions of the mandible and maxilla: a clinicopathologic and cytometric study. Oral Surg Oral Med Oral Pathol 1987;64:44–49. [CrossRef] [PubMed] [Google Scholar]
  8. Abdo EN, Alves LC, Rodrigues AS, Mesquita RA, Gomez RS. Treatment of a central giant cell granuloma with inra lesional corticosteroïds. Brit J Oral Maxilfac Surg 2005;43: 74–76. [CrossRef] [Google Scholar]
  9. Kurtz M, Mesa M, Alberto P. Treatment of central giant cell lesion of the mandible with intralesional glucocorticosteroids. Oral Surg Oral Med Oral Path Oral Rad Endo 2001;91:636–637. [CrossRef] [Google Scholar]
  10. De Lange J, Van Den Akker HP, Van Den Berg H, Richel DJ, Gortzak RA. Limited regression of central giant cell granuloma by interferon alpha after failed calcitonin therapy: a report of two cases. Int J Oral Maxillofac Surg 2006b;35: 865–869. [CrossRef] [PubMed] [Google Scholar]
  11. Schreuder WH, Coumou AW, Kessler PA, de Lange J. Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab. J Oral Maxillofac Surg 2014;72: 1301–1309. [CrossRef] [PubMed] [Google Scholar]
  12. Gupta B, Stanton N, Coleman H, White C, Singh J. A novel approach to the management of a central giant cell granuloma with denosumab: a case report and review of current treatments. J Craniomaxillofac Surg 2015;43:1127–1132. [CrossRef] [PubMed] [Google Scholar]
  13. Naidu A, Malmquist MP, Denham CA, Schow SR. Management of central Giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg 2014;72:2469–2484. [CrossRef] [PubMed] [Google Scholar]
  14. Schreuder WH, van den Berg H, Westermann AM, Peacock ZS, de Lange J. Pharmacological and surgical therapy for the central giant cell granuloma: a long-term retrospective cohort study. J Craniomaxillofac Surg 2017;45:232–243. [CrossRef] [PubMed] [Google Scholar]
  15. De Lange J, van den Akker HP, van den Berg H. Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:603–615. [CrossRef] [PubMed] [Google Scholar]
  16. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind study. J Clin Oncol 2010;28:5132–5139. [CrossRef] [PubMed] [Google Scholar]
  17. Bredell M, Rordorf T, Kroiss S, Rücker M, Zweifel DF, Rostetter C. Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study. J Oral Maxillofac Surg 2017;76:775–784. [CrossRef] [PubMed] [Google Scholar]
  18. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275–280. [CrossRef] [PubMed] [Google Scholar]
  19. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013;14:901–908. [CrossRef] [PubMed] [Google Scholar]
  20. Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, Asami Y, Inoue T, Y oneda T. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase-II trial. Ann Oncol 2015;26:2149–2154. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.